143 related articles for article (PubMed ID: 19056675)
21. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Gao Y; Fotovati A; Lee C; Wang M; Cote G; Guns E; Toyota B; Faury D; Jabado N; Dunn SE
Mol Cancer Ther; 2009 Dec; 8(12):3276-84. PubMed ID: 19996271
[TBL] [Abstract][Full Text] [Related]
22. The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
Woolford LB; Southgate TD; Margison GP; Milsom MD; Fairbairn LJ
J Gene Med; 2006 Jan; 8(1):29-34. PubMed ID: 16075413
[TBL] [Abstract][Full Text] [Related]
23. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
[TBL] [Abstract][Full Text] [Related]
24. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts.
Clemons M; Kelly J; Watson AJ; Howell A; McElhinney RS; McMurry TB; Margison GP
Br J Cancer; 2005 Nov; 93(10):1152-6. PubMed ID: 16278661
[TBL] [Abstract][Full Text] [Related]
25. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
[TBL] [Abstract][Full Text] [Related]
26. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Fontijn D; Adema AD; Bhakat KK; Pinedo HM; Peters GJ; Boven E
Mol Cancer Ther; 2007 Oct; 6(10):2807-15. PubMed ID: 17938272
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
28. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.
D'Atri S; Graziani G; Lacal PM; Nisticò V; Gilberti S; Faraoni I; Watson AJ; Bonmassar E; Margison GP
J Pharmacol Exp Ther; 2000 Aug; 294(2):664-71. PubMed ID: 10900246
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
[TBL] [Abstract][Full Text] [Related]
30. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
[TBL] [Abstract][Full Text] [Related]
31. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.
Jiang X; Reardon DA; Desjardins A; Vredenburgh JJ; Quinn JA; Austin AD; Herndon JE; McLendon RE; Friedman HS
J Neurooncol; 2013 Aug; 114(1):135-40. PubMed ID: 23686298
[TBL] [Abstract][Full Text] [Related]
32. Impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells.
Kewitz S; Stiefel M; Kramm CM; Staege MS
Leuk Res; 2014 Jan; 38(1):138-43. PubMed ID: 24284332
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Chakravarti A; Erkkinen MG; Nestler U; Stupp R; Mehta M; Aldape K; Gilbert MR; Black PM; Loeffler JS
Clin Cancer Res; 2006 Aug; 12(15):4738-46. PubMed ID: 16899625
[TBL] [Abstract][Full Text] [Related]
34. Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.
Bobola MS; Tseng SH; Blank A; Berger MS; Silber JR
Clin Cancer Res; 1996 Apr; 2(4):735-41. PubMed ID: 9816224
[TBL] [Abstract][Full Text] [Related]
35. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
36. miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely.
Xiao S; Yang Z; Qiu X; Lv R; Liu J; Wu M; Liao Y; Liu Q
Oncotarget; 2016 Aug; 7(31):50229-50238. PubMed ID: 27384876
[TBL] [Abstract][Full Text] [Related]
37. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
38. A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Chen TC; Cho HY; Wang W; Nguyen J; Jhaveri N; Rosenstein-Sisson R; Hofman FM; Schönthal AH
Cancer Lett; 2015 Mar; 358(2):144-151. PubMed ID: 25524552
[TBL] [Abstract][Full Text] [Related]
39. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
40. Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
